Drug major’s decision
The decision by Johnson & Johnson not to enforce patents on TB drug bedaquiline is a boon for low- and middle-income countries. Treatment for MDR/XDR is expensive and of long duration. The move will create avenues for the production of generic bedaquiline, which will have a great impact on TB control in India.
Dr. Thomas Palocaren,
